ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program YONKERS, NY--(Marketwired - March 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...